UY25823A1 - Derivados de indol y su uso en el tratamiento de la migrana - Google Patents

Derivados de indol y su uso en el tratamiento de la migrana

Info

Publication number
UY25823A1
UY25823A1 UY25823A UY25823A UY25823A1 UY 25823 A1 UY25823 A1 UY 25823A1 UY 25823 A UY25823 A UY 25823A UY 25823 A UY25823 A UY 25823A UY 25823 A1 UY25823 A1 UY 25823A1
Authority
UY
Uruguay
Prior art keywords
treatment
migranes
indol
derivatives
hemesis
Prior art date
Application number
UY25823A
Other languages
English (en)
Spanish (es)
Inventor
Ronald James Ogilvie
Cristopher Ian Dallman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY25823A1 publication Critical patent/UY25823A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electroluminescent Light Sources (AREA)
  • Lasers (AREA)
UY25823A 1998-11-27 1999-11-29 Derivados de indol y su uso en el tratamiento de la migrana UY25823A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9825988.0A GB9825988D0 (en) 1998-11-27 1998-11-27 Indole derivatives

Publications (1)

Publication Number Publication Date
UY25823A1 true UY25823A1 (es) 2001-08-27

Family

ID=10843140

Family Applications (2)

Application Number Title Priority Date Filing Date
UY25823A UY25823A1 (es) 1998-11-27 1999-11-29 Derivados de indol y su uso en el tratamiento de la migrana
UY25825A UY25825A1 (es) 1998-11-27 1999-11-30 Procedimiento para preparar derivados de indol

Family Applications After (1)

Application Number Title Priority Date Filing Date
UY25825A UY25825A1 (es) 1998-11-27 1999-11-30 Procedimiento para preparar derivados de indol

Country Status (53)

Country Link
US (2) US20020013358A1 (enrdf_load_html_response)
EP (1) EP1135381B1 (enrdf_load_html_response)
JP (1) JP3777094B2 (enrdf_load_html_response)
KR (1) KR100413739B1 (enrdf_load_html_response)
CN (1) CN1131860C (enrdf_load_html_response)
AP (1) AP2001002149A0 (enrdf_load_html_response)
AR (1) AR024232A1 (enrdf_load_html_response)
AT (1) ATE273300T1 (enrdf_load_html_response)
AU (1) AU754731B2 (enrdf_load_html_response)
BG (1) BG64706B1 (enrdf_load_html_response)
BR (1) BR9915692A (enrdf_load_html_response)
CA (1) CA2352392C (enrdf_load_html_response)
CO (1) CO5150178A1 (enrdf_load_html_response)
CR (1) CR6325A (enrdf_load_html_response)
CU (1) CU23269A3 (enrdf_load_html_response)
CZ (1) CZ295472B6 (enrdf_load_html_response)
DE (1) DE69919388T2 (enrdf_load_html_response)
DK (1) DK1135381T3 (enrdf_load_html_response)
DZ (1) DZ2948A1 (enrdf_load_html_response)
EA (1) EA003551B1 (enrdf_load_html_response)
EE (1) EE04914B1 (enrdf_load_html_response)
ES (1) ES2224701T3 (enrdf_load_html_response)
GB (1) GB9825988D0 (enrdf_load_html_response)
GC (1) GC0000113A (enrdf_load_html_response)
GE (1) GEP20043183B (enrdf_load_html_response)
GT (1) GT199900202A (enrdf_load_html_response)
HK (1) HK1042898B (enrdf_load_html_response)
HN (1) HN1999000196A (enrdf_load_html_response)
HR (1) HRP20010398B1 (enrdf_load_html_response)
HU (1) HUP0105308A3 (enrdf_load_html_response)
ID (1) ID28802A (enrdf_load_html_response)
IL (1) IL141663A (enrdf_load_html_response)
IS (1) IS2238B (enrdf_load_html_response)
MA (1) MA26708A1 (enrdf_load_html_response)
MY (1) MY124078A (enrdf_load_html_response)
NO (1) NO320798B1 (enrdf_load_html_response)
NZ (1) NZ510055A (enrdf_load_html_response)
OA (1) OA11671A (enrdf_load_html_response)
PA (1) PA8485701A1 (enrdf_load_html_response)
PE (1) PE20001299A1 (enrdf_load_html_response)
PL (1) PL194503B1 (enrdf_load_html_response)
PT (1) PT1135381E (enrdf_load_html_response)
RS (1) RS50002B (enrdf_load_html_response)
SI (1) SI1135381T1 (enrdf_load_html_response)
SK (1) SK285774B6 (enrdf_load_html_response)
SV (1) SV1999000204A (enrdf_load_html_response)
TN (1) TNSN99221A1 (enrdf_load_html_response)
TR (1) TR200101493T2 (enrdf_load_html_response)
TW (1) TWI246512B (enrdf_load_html_response)
UA (1) UA68402C2 (enrdf_load_html_response)
UY (2) UY25823A1 (enrdf_load_html_response)
WO (1) WO2000032589A1 (enrdf_load_html_response)
ZA (1) ZA200102681B (enrdf_load_html_response)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
BRPI0409127A (pt) 2003-04-11 2006-03-28 Pfizer combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio
GB0317229D0 (en) * 2003-07-23 2003-08-27 Pfizer Ltd Improved process
US6927296B2 (en) 2003-07-23 2005-08-09 Pfizer Inc. Process
US20080287519A1 (en) * 2007-05-01 2008-11-20 Marioara Mendelovici Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide
EP2038273A1 (en) * 2007-05-29 2009-03-25 Plus Chemicals B.V. A process for preparing 5-bromo-3-[(r)-1-methyl-pyrrolidin-2-ylmethyl]-1h-indole
WO2009077858A2 (en) * 2007-12-17 2009-06-25 Actavis Group Ptc Ehf Novel hemioxalate salt of eletriptan
WO2010097703A1 (en) * 2009-02-25 2010-09-02 Actavis Group Ptc Ehf Highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan n-oxide impurity
WO2010116386A2 (en) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Novel polymorph of eletriptan hydrobromide and process for the preparation thereof
WO2011089614A1 (en) * 2010-01-19 2011-07-28 Sms Pharmaceuticals Limited PROCESS FOR PREPARING ELETRIPTAN HYDROBROMIDE HAVING α-FORM
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
CN103893112A (zh) * 2012-12-31 2014-07-02 重庆圣华曦药业股份有限公司 氢溴酸依来曲普坦注射液
CN107954947A (zh) * 2016-10-14 2018-04-24 北京莱瑞森医药科技有限公司 沃替西汀氢溴酸盐晶型c及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
FR2624732B1 (fr) 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
US5474784A (en) 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
KR0179053B1 (ko) 1990-10-15 1999-03-20 알렌 제이.스피겔 인돌 유도체
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9510223D0 (en) 1995-05-20 1995-07-19 Pfizer Ltd Therapeutic agent
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
US5998462A (en) * 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) * 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
ES2163291T3 (es) 1997-07-03 2002-01-16 Pfizer Composiciones farmaceuticas que contienen eletriptan hemisulfato y cafeina.

Also Published As

Publication number Publication date
EP1135381A1 (en) 2001-09-26
DK1135381T3 (da) 2004-11-15
CO5150178A1 (es) 2002-04-29
EA200100297A1 (ru) 2001-08-27
PL347928A1 (en) 2002-04-22
CU23269A3 (es) 2008-04-09
KR100413739B1 (ko) 2004-01-03
TNSN99221A1 (fr) 2005-11-10
ES2224701T3 (es) 2005-03-01
HRP20010398A2 (en) 2002-06-30
CN1328554A (zh) 2001-12-26
IL141663A0 (en) 2002-03-10
HN1999000196A (es) 2005-11-26
PA8485701A1 (es) 2000-09-29
NZ510055A (en) 2004-11-26
PL194503B1 (pl) 2007-06-29
US20020013358A1 (en) 2002-01-31
HK1042898B (zh) 2004-10-08
IL141663A (en) 2004-05-12
NO20012584L (no) 2001-07-27
JP2002531449A (ja) 2002-09-24
US7238723B2 (en) 2007-07-03
SK285774B6 (sk) 2007-08-02
OA11671A (en) 2005-01-12
EP1135381B1 (en) 2004-08-11
NO320798B1 (no) 2006-01-30
ATE273300T1 (de) 2004-08-15
AU754731B2 (en) 2002-11-21
PE20001299A1 (es) 2000-12-01
CA2352392A1 (en) 2000-06-08
GC0000113A (en) 2005-06-29
MY124078A (en) 2006-06-30
HK1042898A1 (en) 2002-08-30
CA2352392C (en) 2006-01-24
GT199900202A (es) 2001-05-19
UA68402C2 (en) 2004-08-16
YU18801A (sh) 2003-07-07
EE04914B1 (et) 2007-10-15
ZA200102681B (en) 2002-07-02
EA003551B1 (ru) 2003-06-26
AR024232A1 (es) 2002-09-25
CN1131860C (zh) 2003-12-24
TR200101493T2 (tr) 2002-02-21
RS50002B (sr) 2008-09-29
UY25825A1 (es) 2000-08-21
HUP0105308A3 (en) 2003-01-28
JP3777094B2 (ja) 2006-05-24
AU6225399A (en) 2000-06-19
DZ2948A1 (fr) 2004-03-15
BG105539A (en) 2001-12-29
US20050131237A1 (en) 2005-06-16
SK6992001A3 (en) 2002-01-07
IS2238B (is) 2007-05-15
BG64706B1 (bg) 2005-12-30
KR20010080594A (ko) 2001-08-22
PT1135381E (pt) 2004-10-29
HRP20010398B1 (en) 2004-12-31
DE69919388D1 (de) 2004-09-16
TWI246512B (en) 2006-01-01
SI1135381T1 (en) 2004-10-31
AP2001002149A0 (en) 2001-06-30
CZ20011839A3 (cs) 2001-10-17
NO20012584D0 (no) 2001-05-25
CZ295472B6 (cs) 2005-08-17
DE69919388T2 (de) 2005-09-29
SV1999000204A (es) 2000-10-16
EE200100285A (et) 2002-08-15
CR6325A (enrdf_load_html_response) 2008-07-02
WO2000032589A1 (en) 2000-06-08
GB9825988D0 (en) 1999-01-20
BR9915692A (pt) 2001-08-14
MA26708A1 (fr) 2004-12-20
GEP20043183B (en) 2004-02-25
HUP0105308A2 (hu) 2002-05-29
IS5868A (is) 2001-02-27
ID28802A (id) 2001-07-05

Similar Documents

Publication Publication Date Title
UY25823A1 (es) Derivados de indol y su uso en el tratamiento de la migrana
BR9206810A (pt) Derivados de indol
DE60018274D1 (de) Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden
MA31707B1 (fr) Dérivés de benzimidazole et d'indole substitués par de l'oxadiazole et oxazole comme inhibiteurs de dgat1
BR9707136A (pt) Derivados morfinóides condesados em heterociclo (ii)
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
TR200102161T2 (tr) Pirazino(aza)indol türevleri.
NO20042123L (no) Staurosporinderivater som inbibitorer av FLT3 reseptor tyrosin kinase aktivitet
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
LU91407I2 (fr) Sunitinib optionnellement sous la forme d'un sel pharmaceutiquement acceptable y compris le sel l-malate (sutent)
GB0504828D0 (en) Therapeutic agents
PA8597301A1 (es) Derivados de imidazol-4-il-etinil-piridina
BR9306012A (pt) Derivados de indóis como antagonistas 5-ht1
CY1111946T1 (el) To (1s, 5s) -3-(5,6-διχλωρο-3-πυριδινυλο)-3, 6-διαζαδικυ-κλο[3.2.0]επτανιο ειναι ενας αποτελεσματiκος αναλγητικος παραγοντας
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
EE05305B1 (et) Zolmitriptaani sisaldav ravimpreparaat, meetod selle valmistamiseks ning seda sisaldav intranasaalse manustamise vahend
DK1581538T3 (da) Tetracykliske 3-substituerede indoler med serotoninreceptoraffinitet
IS6426A (is) Píperasínómetýlbensamíð sem delta-ópíóíðviðtakagerandefni
GB0311349D0 (en) Therapeutic agents, compositions, preparations and uses
TR199701397T1 (xx) Pirolidinil metil indol tuzu.
FI973382A0 (fi) Migreenin hoitoon käytettävä indolijohdannainen
Johnson Characterization of the role of serotonin receptor subtypes (5-HT1 and 5-HT2) and nitric oxide in guinea pig dural plasma protein extravasation

Legal Events

Date Code Title Description
ABAN Application deemed to be withdrawn (no publication fee paid)

Effective date: 20090309